EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation

The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option, targeting EGFR T790M with third-generation EGFR TKI is now established as...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Sehhoon, Ku, Bo Mi, Jung, Hyun Ae, Sun, Jong-Mu, Ahn, Jin Seok, Lee, Se-Hoon, Park, Keunchil, Ahn, Myung-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577810/
https://www.ncbi.nlm.nih.gov/pubmed/32599977
http://dx.doi.org/10.4143/crt.2020.278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577810/
https://www.ncbi.nlm.nih.gov/pubmed/32599977
http://dx.doi.org/10.4143/crt.2020.278

Ejemplares similares